| 英文名稱(chēng) | Osilodrostat (LCI699) |
|---|---|
| 中文名稱(chēng) | 奧西卓司他 |
| CAS號(hào) | 928134-65-0 |
| 分子式 | C13H10FN3 |
| 分子量 | 227.24 |
| 外觀 | White to yellow pwder |
| 儲(chǔ)存條件 | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
| 規(guī)格 | 庫(kù)存 | 目錄價(jià) | 會(huì)員專(zhuān)享價(jià) | 數(shù)量 |
|---|---|---|---|---|
| 1 mg | 3-5days | ¥350.00 | 登錄后可見(jiàn) | |
| 5 mg | 3-5days | ¥660.00 | 登錄后可見(jiàn) | |
| 10 mg | 3-5days | ¥1150.00 | 登錄后可見(jiàn) |
| 英文名稱(chēng) | Osilodrostat (LCI699) |
|---|---|
| 中文名稱(chēng) | 奧西卓司他 |
| CAS號(hào) | 928134-65-0 |
| 分子式 | C13H10FN3 |
| 分子量 | 227.24 |
| 外觀 | White to yellow pwder |
| 儲(chǔ)存條件 | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
Osilodrostat, also known as LCI699, is a potent inhibitor of 11β-hydroxylase, the enzyme which catalyzes the final step of cortisol synthesis. LCI699 may thus be a potential new treatment for all forms of Cushing's syndrome. Current evidence indicates that the novel aldosterone inhibitor LCI699 is an effective and well-tolerated antihypertensive agent that lowers plasma aldosterone concentration and produces a mild ACTH-stimulated cortisol response suppressive effect.